Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan-TBI vs Cyclophosphamide-TBI in Advanced MDS or MDS-Related AML Undergoing PBSCT
NCT00005866Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2000
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of busulfan in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Event-free survival. Started Feb 2000; status: completed.
02
Drugs
busulfan
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00005866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005866.